Squamous cell carcinomas of the skin (SCC) are a leading cause of death in organ transplant recipients and treatment of non-melanoma skin cancers, of which SCC is the second most frequent type, account for 4.5% of all Medicare cancer costs. The incidence and malignancy of SCC are greatly increased in patients with decreased T cell function, suggesting a role for the immune system in controlling these tumors. T cells are found within SCC but fail to control tumor growth. Preliminary results are presented that SCC evade the immune system by two newly identified mechanisms. First, by failing to express E-selectin on tumor vessels, SCC evade the population of antigen-experienced skin homing T cells most capable of recognizing the tumor. Second, by recruiting FOXP3+ regulatory T cells (Treg), SCC create a local environment of immune suppression around the tumor. Imiquimod, a TLR7 agonist effective in the treatment of skin cancers, neutralizes both of these defenses, inducing expression of E-selectin on tumor vessels, restoring the ability of CLA+ skin homing T cells to enter the tumor and reducing the % FOXP3+ Treg to levels found in normal skin. Studies described in this proposal focus on determining how SCC inhibit vascular E-selectin and recruit Treg with the goal of developing novel agents for the treatment of SCC and their premalignant precursor lesions, actinic keratoses (AK). Additional studies focus on determining the mechanisms by which imiquimod induces vascular E-selectin and restores T cell homing, with the goal of developing agents that can treat established SCC without the risk of widespread immune stimulation that is a concern with TLR agonists such as imiquimod. Hypotheses are presented that nitric oxide (NO) produced by dendritic cells (DC) within SCC inhibit vascular E-selectin and that recruitment of NO-producing DC and Treg both occur via CCR2. Proposed studies investigate if inhibition of CCR2 function, induction of E-selectin on tumor vessels and inhibition of Treg recruitment can enhance the immunologic response to SCC. These questions will be investigated first in vitro and then in immunodeficient mice grafted with human SCC tumors. Lastly, studies are proposed to determine if aberrant homing and Treg recruitment also occur in AK. If so, therapies that induce E-selectin and inhibit recruitment of Treg may be effective in the treatment of these lesions, inducing their immunologic destruction before they progress to SCC. Novel therapies will be evaluated in vitro and in mice grafted with human AK. These studies address two long-term interests of NIAMS: study of the skin as an immune organ and study of the role of the immune system in the development and treatment of skin cancer.
These studies focus on the development of novel therapies for squamous cell carcinomas and their premalignant precursor lesions that are safe for use in normal and immunosuppressed individuals. The skin is an accessible tissue in which to study tumor immunity because immune reactions in the skin are visible, easily sampled and can be manipulated with topical medications. Because impaired T cell homing and recruitment of regulatory T cells occur in many human malignancies, findings and novel therapies arising from this work should be applicable to the treatment of other types of human cancer.
|Schlapbach, Christoph; Gehad, Ahmed; Yang, Chao et al. (2014) Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med 6:219ra8|
|Watanabe, Rei; Teague, Jessica E; Fisher, David C et al. (2014) Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol 150:776-9|
|Fischer, Sebastian; Lian, Christine G; Kueckelhaus, Maximilian et al. (2014) Acute rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant 19:531-44|
|Guenova, Emmanuella; Watanabe, Rei; Teague, Jessica E et al. (2013) TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19:3755-63|
|Hijnen, Dirkjan; Knol, Edward F; Gent, Yoony Y et al. (2013) CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-ýý, IL-13, IL-17, and IL-22. J Invest Dermatol 133:973-9|
|Dowlatshahi, Mitra; Huang, Victor; Gehad, Ahmed E et al. (2013) Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol 133:1879-89|
|Clark, Rachael A; Watanabe, Rei; Teague, Jessica E et al. (2012) Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 4:117ra7|
|Cedeno-Laurent, Filiberto; Watanabe, Rei; Teague, Jessica E et al. (2012) Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 119:3534-8|
|Clark, Rachael A; Shackelton, Jeffrey B; Watanabe, Rei et al. (2011) High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. Blood 117:1966-76|
|Clark, Rachael A (2011) Gone but not forgotten: lesional memory in psoriatic skin. J Invest Dermatol 131:283-5|
Showing the most recent 10 out of 16 publications